Immunocore

Description

Immunocore engineers ImmTAX T cell receptor–based therapeutics to activate or suppress immune responses, advancing bispecific TCR candidates and KIMMTRAK to treat patients with cancer, infectious, and autoimmune diseases.

Immunocore is located in the Oxford ecosystem.

Related

• ImmaticsImmatics develops PRAME-targeted immunotherapies, advancing T-cell receptor cell therapies and bispecific molecules such as IMA203 and…
• Asgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• Ability PharmaceuticalsAbility Pharmaceuticals develops oral targeted anticancer compounds that induce selective autophagy-mediated cytotoxicity in cancer cells;…
• CytuvaxCytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating…
• Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…